This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Gender Disparities in Academic Outcomes Among Graduates of a Canadian MD-PhD Program.
Clinical and investigative medicine. Medecine clinique et experimentale · 2023
Latest funding
- $1,143,675
Exploring novel protein interactions in RAF mutant tumors to reveal new therapeutic opportunities
CIHR · 2024 · Nominated PI
- $120,000
Characterizing the multifunctional roles of CRAF in mediating MAPKi resistance in Non-V600 BRAF mutant cancers
CIHR · 2024 · Supervisor
- $120,000
Investigating the Role of RAS in Resistance to Targeted Therapies in BRAF-Mutant Colorectal Cancer
CIHR · 2024 · Supervisor
1 publications.
Gender Disparities in Academic Outcomes Among Graduates of a Canadian MD-PhD Program.
Romero JM, Sorin M, Dankner M, Whittaker H, Rose A, Trasler J, Eisenberg MJ
Exploring novel protein interactions in RAF mutant tumors to reveal new therapeutic opportunities
Principal investigators: Rose, April A
Keywords: Bioid Proteomics; Braf; Cancer; Craf; Drug Resistance; Genomics; Kinase Inhibitors; Targeted Therapies
Characterizing the multifunctional roles of CRAF in mediating MAPKi resistance in Non-V600 BRAF mutant cancers
Principal investigators: Rousselle, Emmanuelle J
Keywords: Cell Cycle; Cellular Proliferation; Craf; Mapk Independent; Mapk Inhibitors; Non-V600 Braf; Protein Localization; Protein-Protein Interactions; Rb; Treatment Resistance
Investigating the Role of RAS in Resistance to Targeted Therapies in BRAF-Mutant Colorectal Cancer
Principal investigators: Maxwell, Jennifer L
Keywords: Braf + Mek Inhibition; Braf V600 Mutations; Braf:Craf Heterodimerization; Clonogenic Growth Assays; Colorectal Cancer; Egfr Inhibition; Immunoblotting; Ras Mutations; Treatment Resistance; Xenografts
Defining the critical genomic dependencies of non-V600 BRAF mutant tumors to optimize targeted therapeutic strategies
Principal investigators: Riaud, Melody
Keywords: Crispr/Cas9 Screen; Drug Resistance; Non-V600 Braf Mutants Tumors; Targeted Therapies
Evaluating mutant NRAS as a molecular mediator of immunotherapy resistance in melanoma
Principal investigators: Rose, April A
Keywords: Biomarkers; Immunotherapy; Macrophage; Mdsc; Melanoma; Next Generation Sequencing; Nras; Phenotype Switching; Single Cell Rna Sequencing; Tgf-Beta
Prize - 202109PJT - Evaluating mutant NRAS as a molecular mediator of immunotherapy resistance in melanoma
Principal investigators: Rose, April A
Keywords: Biomarkers; Immunotherapy; Macrophage; Mdsc; Melanoma; Next Generation Sequencing; Nras; Phenotype Switching; Single Cell Rna Sequencing; Tgf-Beta
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Jacquetta Trasler and April Rose: 1 shared paper
- Jacquetta Trasler and Mark Sorin: 1 shared paper
- April Rose and Mark Sorin: 1 shared paper
- Pediatrics
- Human Genetics
- Other
Co-authors at McGill University, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.